JAN RYAN VILORIA: Open Payments
NPI 1538611058 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$722 in 38 payments from 13 companies in 2025. Trend: 2023 $604 · 2024 $595 · 2025 $722
Food & beverage: $722
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $139 |
| Lilly USA, LLC | 5 | $107 |
| AstraZeneca Pharmaceuticals LP | 5 | $97 |
| Novo Nordisk Inc | 5 | $96 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $58 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $54 |
| PFIZER INC. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
Products named: VRAYLAR, JARDIANCE, FARXIGA, MOUNJARO, Kerendia, QULIPTA, Rybelsus, REXULTI.
Industry payments across MD — which companies pay providers there.
